Homegrown pharma major Lupin on Friday said it has received establishment inspection report (EIR) from the US health regulator for its Aurangabad, Maharashtra, facility with no action indicated.
The inspection for the facility was carried out by the US Food and Drug Administration (USFDA) between February 10 and February 14, 2020, and concluded with no observations, the company said in a regulatory filing.
Commenting on the receipt of the EIR, Lupin Managing Director Nilesh Gupta said, This takes us a step forward in our efforts of enhancing our compliance and quality standards across all our manufacturing sites."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app